Advanced Pancreatic Ductal Adenocarcinoma (PDAC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Advanced
Pancreatic Ductal Adenocarcinoma (PDAC) Market Outlook
Thelansis’s “Advanced Pancreatic
Ductal Adenocarcinoma (PDAC) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2025 To 2035” covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
Pancreatic Ductal Adenocarcinoma (PDAC) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced
Pancreatic Ductal Adenocarcinoma (PDAC) Overview
Advanced
pancreatic ductal adenocarcinoma (PDAC) is an exceptionally lethal, rapidly
progressive gastrointestinal malignancy originating from the exocrine
compartment of the pancreas. The disease is fundamentally defined by
near-universal KRAS mutations and the formation of an
intensely dense, hypovascular, and profoundly immunosuppressive desmoplastic
stroma; this unique microenvironment acts as a formidable physical and
biological barrier, rendering the tumor highly resistant to traditional
chemotherapies, targeted agents, and immunotherapies. Because the disease
progresses insidiously, the vast majority of patients present with unresectable
or widely metastatic disease, precluding any curative surgical intervention.
Consequently, the modern frontline standard of care is entirely palliative,
relying on highly aggressive, multi-agent cytotoxic chemotherapy
regimens—specifically FOLFIRINOX or the combination of gemcitabine and
nab-paclitaxel—to transiently stall disease progression. While precision
oncology has established a vital, albeit narrow, foothold—most notably the use
of targeted PARP inhibitors for maintenance therapy in the small subset of
patients harboring germline BRCA mutations—overcoming the
profound intrinsic chemoresistance of advanced PDAC remains one of the most
severe unmet clinical needs in modern oncology.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g., drug uptake and erosion)
datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment